COMPANY:

Interpace Biosci

"Interpace Biosciences, Inc...announced new real-world clinical utility data for their ThyGeNEXT® + ThyraMIR®v2 combination test platform to assess the malignancy risk of indeterminate thyroid nodules (ITN). The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119)."

"Interpace Biosciences, Inc...announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel (ThyGeNEXT®) and a microRNA (miRNA) risk classifier. The new data demonstrates that the addition of miRNA pairwise expression profiling (ThyraMIR®v2) provides clinically and statistically superior risk stratification of indeterminate thyroid nodules (ITN) beyond that of the algorithmic classification analysis provided by the original ThyraMIR® assay."

"Interpace Biosciences, Inc...has announced that in association with Miroculus, Inc...it will optimize next generation sequencing (NGS) library preparation utilizing its digital microfluidics (DMF) technology. Also working in conjunction with Miroculus and Interpace Biosciences will be Twist Bioscience Corporation...Interpace Diagnostics will utilize Twist Bioscience’s chemistries for library preparation and hybridization capture for the automation of Interpace’s custom NGS panels, and Miroculus’s DMF instrument, the Miro Canvas, to enable low volume, accurate, and precise sample preparation for its genetic tests targeting specific markers in Endocrine and GI cancers."

"Interpace Biosciences, Inc...announced today that the National Correct Coding Initiative (NCCI) program issued a response on behalf of the Centers for Medicare & Medicaid Services (CMS) stating that the previously announced billing policy reimbursement for its ThyGeNEXT (O245U) and ThyraMIR (oo18U) tests, disclosed by it in a press release dated January 28, 2022, has been changed retroactive to January 1, 2022. As a result, the Company will continue billing for both tests according to its Laboratory Coverage Determination (LCD) as originally set by Novitas."

"Interpace...announced that it just became aware that the Centers for Medicare & Medicaid Services (CMS) issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service."

"Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc...announced today that it will offer a new capability in providing Digital Spatial Profiling services using the novel GeoMx® testing platform. GeoMx® combines the benefits of IHC/FISH and high-throughput expression analysis into one streamlined tissue multiplexing assay. Protein and nucleic acids can now be measured by Interpace with an unparalleled level of precision, from whole tissue to single cell, in either an FFPE sample or frozen tissue section."

"Interpace Biosciences, Inc...announced today that eviCore Healthcare...has updated their laboratory management guidelines to include positive coverage for ThyGeNEXT® and ThyraMIR®. This update, which impacts approximately 27 health plans nationwide covering 100 million lives, is effective on July 1, 2021. This means that after the effective date, claims for ThyGeNEXT and ThyraMIR which meet eviCore’s criteria for coverage will be considered medically necessary and processed as a covered service."

"Interpace Biosciences, Inc...announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service...The new PLA code for ThyGeNEXT® is 0245U and the reimbursement for this code remains $2,919, representing a significant price increase over the prior reimbursement level of $560."

"Interpace Biosciences, Inc. ('Interpace' or 'the Company'), today announced that Blue Cross Blue Shield of Illinois...has entered into an agreement to provide both coverage and in-network status for Interpace’s molecular combination thyroid tests, ThyGeNEXT® and ThyraMIR®. The agreement is effective February 25, 2021."

"Interpace Biosciences, Inc...announced today that the Company’s Diagnostics group has entered in to a contract with Blue Cross Blue Shield of Florida (“Florida Blue”), the largest health plan in Florida. As part of the Agreement, Interpace’s ThyGeNEXT® and ThyraMIR® tests for indeterminate thyroid nodules will be adjudicated as in-network lab services for its 5 million members effective January 1, 2021."